Skin Complications Associated With Interferon-Beta Treatment In Patients With Multiple Sclerosis, Tehran In 2021

This cross-sectional descriptive study at Baqiyatallah Hospital in Tehran included 322 multiple sclerosis (MS) patients and aimed to assess skin complications from interferon beta (IFNβ) treatment. It found that 46% of patients had no skin complications, while 45.2% experienced erythema at the injection site. Notably, there was a significant increase in hair loss severity post-treatment (P < 0.001), with hair loss rising from 29-30% before treatment to 73% after. The likelihood of developing erythema was 2.60 times higher in patients with moderate disease severity. The study suggests that IFNβ treatment in MS patients leads to skin reactions and increased hair loss, recommending further research on hair loss progression and emphasizing the need for physician awareness to manage these complications.